Hims & Hers Health (HIMS) Q3 Earnings: What To Expect

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday afternoon. Here’s what you need to know.

Hims & Hers Health missed analysts’ revenue expectations by 1.1% last quarter, reporting revenues of $544.8 million, up 72.6% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but EBITDA guidance for next quarter missing analysts’ expectations significantly. It added 73,000 customers to reach a total of 2.44 million.

Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Hims & Hers Health’s revenue to grow 44.3% year on year to $579.6 million, slowing from the 77.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3% on average.

Looking at Hims & Hers Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It beat analysts’ revenue estimates by 5%, delivering year-on-year sales growth of 10%. The stock traded up 13.6% on the results.

Investors in the healthcare technology segment have had steady hands going into earnings, with share prices flat over the last month. Hims & Hers Health is down 11.8% during the same time and is heading into earnings with an average analyst price target of $47.77 (compared to the current share price of $46.35).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.